Candid to go public via reverse merger with Rallybio
坦蒂拟通过与Rallybio的反向并购实现上市

Candid Therapeutics will go public through a reverse merger as it seeks to prove whether T cell engagers can shake up the treatment of autoimmune diseases.
上海坦蒂生物医药科技有限公司将通过反向并购上市，力图验证T细胞连接器能否撼动自身免疫性疾病的治疗格局。